Replimune Group, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sushil Patel
- Full Time Employees
- 465
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Unicorn Park Drive Woburn MA United States of America 01801
- IPO Date
- Jul 20, 2018
- CIK
- 0001737953
- Website
- replimune.com
- Similar Companies
- Business
- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, develops oncolytic immunotherapies based on its proprietary RPx platform, which utilizes an engineered herpes simplex virus 1 (HSV-1) backbone to selectively replicate in and destroy tumor cells while stimulating systemic anti-tumor immune responses; its lead product candidate RP1 (vusolimogene oderparepvec) expresses GALV-GP R(-) and human GM-CSF for treating solid tumors including advanced melanoma; RP2 incorporates an anti-CTLA-4 antibody-like protein to enhance T-cell activation; and RP3 expresses multiple immune-activating transgenes including anti-CTLA-4 and immune stimulatory proteins to further potentiate immune responses against cancer. Founded in 2015 and headquartered in Woburn, Massachusetts, the company conducts operations primarily in the United States and the United Kingdom, targeting patients with solid tumors such as melanoma, skin, and other cancers through clinical-stage programs often in combination with checkpoint inhibitors like nivolumab (Opdivo). In recent developments, Replimune submitted a biologics license application (BLA) to the U.S. FDA for RP1 plus nivolumab in advanced melanoma post-anti-PD1 therapy, which received priority review before a complete response letter (CRL) in July 2025; the company resubmitted the BLA in October 2025 with additional data and analyses addressing FDA feedback, earning acceptance and a PDUFA target action date of April 10, 2026; additionally, it announced a proposed $125 million public offering of common stock in November 2024, with a 30-day underwriter option for $18.75 million more, to fund clinical development and operations.
Company News
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Replimune to Present at the Cantor Global Healthcare Conference 2026
Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.
Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Hsbc Holdings PLC Invests $1.03 Million in Replimune Group, Inc. $REPL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm